

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

1" - 23 gauge (blue)

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

Site reactions, sleepiness or drowsiness, dizziness, feeling restless or needing to be constantly moving, abnormal muscle movements including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes

3. What black box warning is associated with this medication?

Increased mortality in elderly patients with dementia-related psychosis.

4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?

234 mg / 156 mg

5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?

117 mg

6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

Deltoid

7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?

156 mg / 117 mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

78mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

To establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with Invega Sustenna.

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Handwashing, wipe injection site with alcohol pads before injection, and keep needle capped until ready to use.

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

Medication may cause a lot of serious side effects.